SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about audited financial results

18 Jun 2018 Evaluate

With reference to the letter dated 28th May, 2018 wherein the company has intimated the schedule of Investors/Analysts call on 29th May, 2018, Aurobindo Pharma has informed about submission of transcript of the analyst / investor call on the Audited Financial Results of the Company for the Year ended 31st March, 2018 of 29th May, 2018 and the same is being uploaded on the website of the Company and is available in the following web link: http://www.aurobindo.com/docs/financial-results/2017-2018/aurobindo-pharma-q4-fy-18-earnings-call-transcript.pdf.

The above information is a part of company’s filings submitted to BSE.

 

Aurobindo Pharma Share Price

1620.10 60.05 (3.85%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: